Schizophrenia Research
Volume 118, Issue 1 , Pages 218-223 , May 2010

Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial

  • Preeta Kaur Narula

      Affiliations

    • Department of Pharmacology, Lady Hardinge Medical College and Associated S.S.K. Hospitals, New Delhi, India
    • Corresponding Author InformationCorresponding author. J – 13/42, Rajouri Garden, New Delhi 110027, India. Tel: +91 9811581034.
    • ,
  • H.S. Rehan

      Affiliations

    • Department of Pharmacology, Lady Hardinge Medical College and Associated S.S.K. Hospitals, New Delhi, India
    • ,
  • K.E.S. Unni

      Affiliations

    • Department of Psychiatry, Lady Hardinge Medical College and Associated S.S.K. Hospitals, New Delhi, India
    • ,
  • Neeraj Gupta

      Affiliations

    • Department of Psychiatry, Lady Hardinge Medical College and Associated S.S.K. Hospitals, New Delhi, India

Received 24 May 2009 ,Revised 29 January 2010 ,Accepted 1 February 2010.

References 

  1. Afshar H, Roohafza H, Mousavi G, Golchin S, Toghianifar N, Sadeghi M, et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J. Psychopharmacol. 2009;23:157–162
  2. Astrup A, Caterson I, Zelissen P, Guy-Grand B, Carruba M, Levy B, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes. Res. 2004;12:1658–1669
  3. Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr. Res. 2003;60:99–100
  4. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight changes in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. J. Clin. Psychiatry. 2001;62:231–238
  5. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes. Res. 2003;11:556–562
  6. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res. 2003;11:722–733
  7. Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin. Neuropharmacol. 2001;24:43–49
  8. Drapalski AL, Rosse RB, Peebles RR, Schwartz BL, Marvel CL, Deutsch SI. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin. Neuropharmacol. 2001;24:290–294
  9. Graham KA, Perkins DO, Edwards LJ, Barrier RC, Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am. J. Psychiatry. 2005;162:118–123
  10. Hester EK, Thrower MR. Current options in the management of olanzapine-associated weight gain. Ann. Pharmacother. 2005;39:302–310
  11. Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y, et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J. Psychopharmacol. 2006;20:75–79
  12. Jayaram MB, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst. Rev. 2006;2:CD005237
  13. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  14. Kim JH, Yim SJ, Nam JH. A 12-week randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr. Res. 2006;82:115–117
  15. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long term olanzapine treatment: weight change and weight related health factors in schizophrenia. J. Clin. Psychiatry. 2001;62:92–100
  16. Klein KM, Theisen F, Knake S, Oertel WH, Hebebrand J, Rosenow F, et al. Topiramate, nutrition and weight change: a prospective study. J. Neurol. Neurosurg. Psychiatry. 2008;79:590–593
  17. Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin. Neuropharmacol. 2005;28:169–175
  18. Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am. J. Psychiatry. 1999;156:312–314
  19. Landmark CJ. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008;22:27–47
  20. Lee C, Wu KH, Habil H, Dyachkova Y, Lee P. Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. Aust. N. Z. J. Psychiatry. 2006;40:437–445
  21. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry. 2009;166:152–163
  22. Lévy E, Agbokou C, Ferreri F, Chouinard G, Margolese HC. Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Can. J. Clin. Pharmacol. 2007;14:234–239
  23. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005;353:1209–1223
  24. Lin YH, Liu CY, Hsiao MC. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin. Neurosci. 2005;59:613–615
  25. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am. J. Psychiatry. 2003;160:290–296
  26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  27. Melkersson KI, Hulting A, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J. Clin. Psychiatry. 2000;61:742–749
  28. Mousavi SGh, Golchin Sh, Afshar H, Afza HRR. Add on topiramate for the pharmacological management of schizophrenia: a double blind randomized clinical trial. Iranian J. Psych. Behav. Sci. 2007;1:16–22
  29. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1–93
  30. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can. J. Psychiatry. 1991;36:239–245
  31. Picard F, Deshaies Y, Lalonde J, Samson P, Richard D. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes. Res. 2000;8:656–663
  32. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition. 2000;16:961–966
  33. Richard D, Picard F, Lemieux C, Lalonde J, Samson P, Deshaies Y. The effects of topiramate and sex hormones on energy balance of male and female rats. Int. J. Obes. Relat. Metab. Disord. 2002;26:344–353
  34. Schneiderhan ME, Marvin R. Is acetazolamide similar to topiramate for reversal of antipsychotic-induced weight gain?. Am. J. Ther. 2007;14:581–584
  35. Smith U, Axelsen M, Hellebo-Johanson E, Lundgren B, Ben-Menachen E. Topiramate, a novel antiepileptic drug, reduces body weight and food intake in obesity. Obes. Res. 2000;8(1S):105
  36. Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin. Emerg. Drugs. 2008;13:383–392
  37. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research, 1994. World Health Organization, Geneva.
  38. Tiihonen J, Halonen P, Wahlbeck K, Repo-Tiihonen E, Hyvärinen S, Eronen M, et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J. Clin. Psychiatry. 2005;66:1012–1015
  39. Tremblay A, Chaput JP, Bérubé-Parent S, Prud'homme D, Leblanc C, Alméras N, et al. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur. J. Clin. Pharmacol. 2007;63:123–134
  40. WHO Technical Report Series 854 . Physical status: the use and interpretation of anthropometry. In: Report of a WHO Expert Committee. Geneva: World Health Organization; 1995;
  41. WHO Technical Report Series 894 . Obesity: preventing and managing the global epidemic. In: Report of a WHO Consultation. Geneva: World Health Organization; 2000;
  42. WHO expert consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–163
  43. York DA, Singer L, Thomas S, Bray GA. Effect of topiramate on body weight and body composition of Osborne–Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition. 2000;16:967–975

PII: S0920-9964(10)00081-2

doi: 10.1016/j.schres.2010.02.001

Schizophrenia Research
Volume 118, Issue 1 , Pages 218-223 , May 2010

Article Tools